Last updated on April 2015

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma


Brief description of study

This randomised, controlled, multicentre trial is designed to assess the efficacy and safety of sequential icotinib plus chemotherapy versus single icotinib as first-line treatment in stage IIIB/IV lung adenocarcinoma patients with EGFR mutation.

Clinical Study Identifier: NCT02103257

Contact Investigators or Research Sites near you

Start Over

Helong Zhang, MD

Autonome Region Xinjiang Uygur Chinese medicine hospital
Urumqi, China
  Connect »

Helong Zhang, MD

Urumqi General Hospital of Lanzhou Military Region General Hospital
Urumqi, China
2.25miles
  Connect »

Helong Zhang, MD

Xinjiang medical university affiliated tumor hospital
Urumqi, China
2.25miles
  Connect »

Helong Zhang, MD

First Affiliated Hospital of Xinjiang Medical University
Urumqi, China
2.67miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.